滚动资讯
FierceBiotechWith Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engineFierceBiotechUS, UK regulators bolster medical device collaboration while lifting tariffsFierceBiotechZeto’s latest EEG device garners FDA 510(k) clearance for outpatient useFierceBiotechAnthropic acquires stealth AI startup Coefficient Bio in $400M deal: reportsEndpoints NewsAmgen seeks to buoy Tepezza with injectable data in face of incoming competitionBioPharma DiveFDA floats new clinical trial reforms; Takeda punts Denali brain drugBioWorldBiggest gainers and losers for March 30-April 3, 2026Endpoints NewsAnthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trialEndpoints NewsTakeda ends partnership with Denali amid restructuringBioPharma DiveNeurocrine to acquire Prader-Will drug in $2.9B Soleno buyoutThermo FisherBlood Preparation Market Is Going to Boom |• Thermo Fisher Scientific • Baxter International - openPR.comAgilentEvercore ISI Adjusts Agilent Technologies Price Target to $140 From $160, Maintains Outperform Rating - marketscreener.com
Endpoints News 2026年4月6日

Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial

Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial

原文
暂时没有全文，请查看原始来源。

目录

59 全部